Canbi  Pharma  Tech  Cyfyngedig

Cyhoeddi canlyniadau clinigol positif therapi moleciwl bach 'gorau yn y dosbarth' Roche

Jul 22, 2024

Ar 18 Gorffennaf, 2024, cyhoeddodd Roche ganlyniadau cadarnhaol ei dreial clinigol Cam 1 o CT moleciwl bach llafar-996 ar gyfer colli pwysau. Dangosodd y data mai 6.1% oedd colled pwysau cyfartalog pobl ordew heb ddiabetes math 2 ar ôl derbyn triniaeth CT-996 am 4 wythnos (p<0.001), which was clinically significant. The complete research data is expected to be announced at the upcoming medical conference.
Mae'r treial CT{0}} a gyhoeddwyd y tro hwn yn astudiaeth cam I o gynnydd dos sengl a lluosog, aml-ran, aml-garfan, ar hap, dwbl-ddall, a reolir gan blasebo, dos sengl a lluosog, sy'n anelu at werthuso diogelwch, goddefgarwch, ffarmacocineteg a ffarmacodynameg o CT-996 mewn oedolion dros bwysau neu ordew sydd â diabetes math 2 neu hebddo.
Dangosodd dadansoddiad fod cleifion yn y grŵp CT-996 wedi colli 7.3% o bwysau eu corff ar ôl pedair wythnos, tra bod y rhai yn y grŵp plasebo wedi colli 1.2%. Roedd y gwahaniaeth rhwng y ddau grŵp yn glinigol arwyddocaol (gwerth gwahaniaeth 6.1%, t<0.001). Pharmacokinetic data supports the once daily oral administration regimen of CT-996. In addition, the research results also indicate that the levels of CT-996 in the blood of subjects were not significantly affected during fasting or after standardized high-fat meals. Therefore, the administration of CT-996 may not require consideration of meal time, making it potentially more flexible to administer. Based on the research data, Roche expects CT-996 to not only be used for blood glucose control and weight loss treatment, but also as an oral weight maintenance therapy for patients after receiving injectable weight loss therapy.

goTop